I really think this is a viable tool that we can use going forward. You know, we were able to metastasize, excuse me, biopsy tumors, sequence the data, assign cluster assignments, and treat patients. And our time from consent to cluster assignments by the end of the trial was maybe three weeks. And so that’s a timeline that I think is compatible with treating real world patients who have metastatic kidney cancer...
I really think this is a viable tool that we can use going forward. You know, we were able to metastasize, excuse me, biopsy tumors, sequence the data, assign cluster assignments, and treat patients. And our time from consent to cluster assignments by the end of the trial was maybe three weeks. And so that’s a timeline that I think is compatible with treating real world patients who have metastatic kidney cancer. And so I think this technology is feasible and doable and translatable to all sorts of clinical practices, not just something for the research field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
